1. Alanya Tosun Ş, Gurbuz T, Cebi A, Tosun A, Gokmen O, Usta M.Association of increased levels of omentin-1 and carotid intima-mediathickness with early signs of cardiovascular risk in patients withpolycystic ovary syndrome: a prospective case control study. J ObstetGynaecol Res. 2022;48(1):169-177. doi:10.1111/jog.15077
2. Asfuroğlu Y, Kan Ö, Asfuroğlu M, Baser E. Association between dryeye and polycystic ovary syndrome: subclinical inflammation may bepart of the process. Eye Contact Lens. 2021;47(1):27-31. doi:10.1097/ICL.0000000000000716
3. Barbakadze L, Kristasashvili J. Antimullerian hormone in cases of differentreproductive pathologies. Georgian Med News. 2014;(232-233):16-21.
4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus WorkshopGroup. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril.2004;81(1):19-25. doi:10.1016/j.fertnstert.2003.10.004
5. Dokuzeylül Güngör N, Güngör K, Yurci A, Cil K, Hatırnaz Ş. Ovariandrilling down-regulates endometrial nuclear factor-κB p65 expressionin women with PCOS: a prospective case-control study. Turk J ObstetGynecol. 2022;19(1):45-50. doi:10.4274/tjod.galenos.2022.44845
6. Gungor ND, Gurbuz T. Pregnancy outcomes of intrauterineinsemination in age-matched young women according to serum anti-mullerian hormone levels. JRM. 2021;66:195-202.
7. Güngör ND, Gürbüz T. Prediction of the number of oocytes based onAMH and FSH levels in IVF candidates. J Surg Med. 2020;4:733-737.doi:10.28982/josam.759207.
8. Gürbüz T, Gökmen O, Demirçivi Bör E, Uluocak A. Investigating therelationship of serum levels of afamin and interleukin-10 with insulinresistance in infertile women with polycystic ovary syndrome. J SurgMed. 2021;5(3):264-268. doi:10.28982/josam.874039.
9. Gürbüz T, Gökmen O, Dokuzeylül Güngör N. Polikistik over sendromubulunan kadınlarda glikoz potasyum oranının tanısal değerinininsülin ile karşılaştırılması . Cukurova Med J. 2021;46(1):381-386. doi.org/10.17826/cumj.782931
10. Gurbuz T, Gokmen O. A Novel Index to overcome the assessmentlimitations of insulin resistance in polycystic ovary syndromehomeostatic model assessment index to red blood cell distributionwidth ratio. JRM. 2021;66(1-2):9-14.
11. Overgaard M, Glintborg D, Christesen HT, Jensen TK, Andersen MS.Maternal prolactin is associated with glucose status and PCOS inpregnancy: odense child cohort. Eur J Endocrinol. 2020;183(3):307-316.doi:10.1530/EJE-20-0144
12. Rudnicka E, Kunicki M, Suchta K, Machura P, Grymowicz M, SmolarczykR. Inflammatory markers in women with polycystic ovary syndrome.Biomed Res Int. 2020;2020:4092470. doi:10.1155/2020/4092470
13. Han Y, Kim HS, Lee HJ, Oh JY, Sung YA. Metabolic effects of polycystic ovarysyndrome in adolescents. Ann Pediatr Endocrinol Metab. 2015;20(3):136-142.doi:10.6065/apem.2015.20.3.136
14. Yilmaz Ö, Calan M, Kume T, Temur M, Yesil P, Senses MY. The effect ofprolactin levels on MPV in women with PCOS. Clin Endocrinol (Oxf).2015;82(5):747-752. doi:10.1111/cen.12647
15. Li L, Yu J, Zhou Z. Mean platelet volume and polycystic ovarysyndrome: a systematic review and meta-analysis. J Int Med Res. 2022;50(1):3000605211067316. doi:10.1177/03000605211067316
16. Yilmaz Ö, Mehmet C, Kelekci S, Temur M. Association between redblood cell distribution width and polycystic ovary syndrome. EndocrRes. 2015;40(4):181-187. doi:10.3109/07435800.2014.987398
17. Saei Ghare Naz M, Mousavi M, Mahboobifard F, Niknam A, RamezaniTehrani F. A meta-analysis of observational studies on prolactinlevels in women with polycystic ovary syndrome. Diagnostics (Basel).2022;12(12):2924. doi:10.3390/diagnostics12122924